Jaguar Health Flags Going Concern Doubt Despite $19M License Windfall

summarizeSummary

Jaguar Health's Q2 2026 10-Q discloses a going concern warning, $3.8M cash, and a $4.1M net loss, despite a $19M licensing deal that improved equity to $4.9M.

check_boxKey Events · Earnings and Guidance · JAGX

• Going Concern Warning

  Management states substantial doubt about the company's ability to continue as a going concern over the next 12 months, citing recurring losses and insufficient cash balances.

• Cash Position

  Cash of $3.8 million and restricted cash of $2.8 million as of June 30, 2026, down from $7.8 million total at the start of the year.

• Net Loss

  Net loss of $4.1 million for the six months ended June 30, 2026, improved from a $21.2 million loss in the prior-year period.

• License Revenue

  Recognized $19.0 million in license revenue from the Woodward agreement, including a $16.0 million upfront fee and a $3.0 million fee to extinguish a repurchase option.

auto_awesomeAnalysis · JAGX · Life Sciences

Jaguar Health's Q2 2026 10-Q reveals a going concern warning, with cash of just $3.8 million and restricted cash of $2.8 million. The company posted a net loss of $4.1 million for the first half of 2026, though a $19.0 million licensing deal with Woodward provided a lifeline. Total liabilities fell sharply to $29.3 million from $57.0 million, and stockholders' equity swung to a positive $4.9 million from a deficit of $18.7 million. However, the company remains under a Nasdaq Mandatory Panel Monitor until May 2027, and a new SEC-approved listing standard requiring a $5.0 million market value of listed securities is currently stayed. The going concern language is the key risk: management states existing cash may not fund operations for one year.